Published by Josh White on 1st June 2023
(Sharecast News) - AstraZeneca has received approval in the United States for the drug combination of 'Lynparza', or olaparib, with abiraterone and prednisone or prednisolone for the treatment of adult patients suffering from metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious BRCA mutations, it announced on Thursday.